Sorafenib is the currently accepted first-line drug used for the treatment of advanced hepatocellular carcinoma,while resistance to sorafenib affects its curative effect.Available studies elucidated multiple mechanisms responsible for the resistance to sorafenib.The up-regulation of EGFR,dysregulation of signal pathways downstream of EGFR,and overexpression of silent information regulator 1 in hepatoma cells as well as epithelial-to-mesenchymal transition and increased autophage ability of hepatoma cells may increase the resistance to sorafenib.Resistance in tumor endothelial cells and the upregulation of hypoxia-induced factor-1α,chemokine and its receptors in the tumor microenvironment may also affect the sensitivity of hepatcellular carcinoma to sorafenib.This review provides an overview of the underlying mechanisms related to resistance to sorafenib of hepatocellular carcinoma.